Department of, Icahn School of Medicine at Mount Sinai, New York, New York.
Department ofMicrobiology, Icahn School of Medicine at Mount Sinai, New York, New York.
J Infect Dis. 2019 Apr 8;219(Suppl_1):S62-S67. doi: 10.1093/infdis/jiy711.
Due to limitations of current influenza virus vaccines, new vaccines that mediate broad protection and show high efficacy against seasonal and pandemic viruses are urgently needed. The conserved stalk of the viral hemagglutinin has been identified as potential target antigen for this new generation of vaccines. A vaccination strategy based on chimeric hemagglutinin (cHA), which refocuses the immune response toward the stalk domain and the conserved neuraminidase, is currently being tested in clinical trials. Here we discuss how to improve the cHA antigens to generate vaccine candidates that both induce a broad antistalk response and target conserved immunosubdominant epitopes in the head domain of the hemagglutinin. These novel constructs, termed mosaic hemagglutinins, should provide enhanced protection and should be tested in clinical trials to assess their improved potential as universal influenza virus vaccine candidates.
由于当前流感病毒疫苗的局限性,迫切需要新的疫苗来介导广泛的保护,并对季节性和大流行病毒显示出高疗效。病毒血凝素的保守茎部已被确定为新一代疫苗的潜在靶抗原。一种基于嵌合血凝素 (cHA) 的疫苗接种策略,该策略将免疫反应重新聚焦到茎域和保守的神经氨酸酶上,目前正在临床试验中进行测试。在这里,我们讨论如何改进 cHA 抗原,以产生既能诱导广泛抗茎反应,又能针对血凝素头部域中保守免疫亚显性表位的疫苗候选物。这些新型构建体,称为嵌合血凝素,应提供增强的保护,并应在临床试验中进行测试,以评估它们作为通用流感病毒疫苗候选物的改进潜力。